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NEWS AND PERSPECTIVES
Currently available drug-eluting stents (DESs)
represent a useful strategy for the prevention of
restenosis using various cytostatic (e.g. rapamycin)
or cytotoxic (e.g. paclitaxel) drugs. However, these
drugs not only inhibit restenosis, but also impair
re-endothelialization, which increases the inci-
dence of late stent thrombosis, which is a rare com-
plication that is associated with high mortality.1,2
These shortcomings demand further research for
the development of a new generation of DESs. The
focal nature of restenosis makes it a highly at-
tractive target for locally delivered gene-silencing
agents, for which it might be possible to separate
therapeutic benefits from unwanted side effects,
by selectively suppressing the pathogenic genes.
Pyrrole–imidazole polyamide (PIP) is a novel gene
silencer that can be designed and synthesized
readily to target any predetermined gene. The ex-
cellent properties of PIP make it more suitable
for use in stent-based delivery platforms than the
normal gene-silencing agents. Therefore, PIP makes
possible stent-based gene-silencing therapy for
restenosis, and it could be a powerful new agent
to usher in a new generation of DESs.
A Novel Gene Silencer
PIP is a new class of synthetic DNA-binding ligands,
which were first identified from duocarmycin A
and distamycin A. These agents can recognize
and bind DNA with sequence specificity, and 
are small synthetic molecules that consist of 
the aromatic rings of N-methylpyrrole and N-
methylimidazole amino acids.3,4 DNA recognition
by PIP depends on an antiparallel side-by-side
pairing of pyrrole and imidazole in the minor
groove. A pairing of imidazole opposite pyrrole
targets a G-C base pair, and pyrrole opposite im-
idazole targets a C-G base pair. A pyrrole/pyrrole
pairing is degenerated and targets the T-A and 
A-T base pairs.4 Synthetic PIP can bind to specific 
nucleotide sequences of double-helical DNA
with high affinity, and block the binding of spe-
cific proteins, including transcription factors.5
The binding constants and specificity of PIP are
not inferior to those of transcription factors.6
Therefore, PIP that target regulatory sequences
can abolish the promoting effect of transcrip-
tion factors and inhibit the expression of the tar-
geted genes at the transcriptional level. Various
types of sequence-specific, DNA-binding PIP
have been developed to suppress gene ex-
pression, by targeting the promoter regions of
enhancer and transcription factor binding ele-
ments.5–8 Also, because PIPs can be designed
and synthesized readily to target any gene of 
interest, they are, therefore, considered to be 
potential effective gene-silencing agents in the
post-genome era.
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A Promising Agent for the 
Development of DESs
Recently, two preclinical studies have provided
evidence for PIP to be used as a local therapeu-
tic agent that targets the pathogenic genes of
restenosis. Yao et al found that a PIP that targets
transforming growth factor-β1 (TGF-β1) inhibits
restenosis and preserves endothelialization in the
injured artery of the rat.9 They designed a PIP to
span the boundary of the AP-1 binding site of the
TGF-β1 promoter; this suppressed TGF-β1 gene
expression in the vascular lesions, which attenuated
restenosis and accelerated re-endothelialization.
In another study, the same group synthesized PIP
that targeted the LOX-1 promoter of the rat and
achieved the same efficacy for attenuating resteno-
sis and preserving endothelialization.10 As shown
in these studies, PIP that target special genes with
a differential effect on the growth of smooth mus-
cle and endothelial cells are of particular interest,
which makes them more optimal agents for DESs
than rapamycin or paclitaxel.
Nucleic acid medicines, such as antisense, ri-
bozymes, decoys, short interfering RNA (siRNA),
and DNAzymes have been developed as gene-
silencing agents. Antisense, ribozymes, siRNA and
decoys tend to degrade easily when they come
into contact with nucleases; therefore, they require
special drug delivery systems, such as viral vectors,
for effective distribution into target cells when
they are used as therapeutic agents in stent-based
delivery platforms.9 Even although DNAzymes
are more resistant to nuclease activity, they also
face challenges in delivery, cellular uptake, and
bioavailability.11 Undoubtedly, this will increase
the technical difficulty of manufacturing stents.
In contrast to these nucleic acid agents, PIP is 
resistant to nucleases and can enter into the nu-
clei of target cells without any particular delivery
system.9,10 Moreover, PIP has a low molecular
weight and is hydrophobic and lipophilic, mak-
ing it pharmacokinetically suitable for loading
onto the metal stent.12 Thus, therapeutic PIPs could
be readily put into mass production at low cost
and loaded directly onto microporous metal stents
without polymer coating, which will usher in a
new generation of DESs.
Future Perspectives
More effort is needed for research and develop-
ment of PIP in the field of DESs. First, PIPs that
have demonstrated efficacy for restenosis in ani-
mal models (e.g. those that target TGF-β1 and
LOX-1) should be loaded onto metal stents for
further translational investigations. However, the
issues of drug safety, recommended therapeutic
dose, and release kinetics need careful considera-
tion before clinical application. Second, more
pathophysiologically relevant genes should serve
as new candidate targets. The pathophysiology of
restenosis has been studied widely and the up-
regulation of several key genes is responsible for
restenosis.13,14 The potential areas for the appli-
cation of PIP are principally where: (1) genes
prevent endothelial healing; (2) genes promote
platelet aggregation and inflammatory cell recruit-
ment; (3) genes promote migration and prolifer-
ation of vascular smooth muscle cells; (4) genes
promote extracellular matrix deposition or pre-
vent its degradation; and (5) genes regulate patho-
genic molecular mediators (cytokines and growth
factors).15 Local delivery of therapeutic PIP using
metal stent delivery systems will exert effects by
selectively suppressing these genes before the
restenosis cascade can be triggered. In considera-
tion of the important clinical consequences of
restenosis after coronary intervention and the
huge market potential for DESs, the potential use
of PIP in DESs is worthy of further research and
development.
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